562 related articles for article (PubMed ID: 29643228)
21. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
22. Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells.
Samudio IJ; Duvvuri S; Clise-Dwyer K; Watt JC; Mak D; Kantarjian H; Yang D; Ruvolo V; Borthakur G
Leuk Lymphoma; 2010 May; 51(5):911-919. PubMed ID: 20423286
[TBL] [Abstract][Full Text] [Related]
23. MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation
Yang J; Jin A; Han J; Chen X; Zheng J; Zhang Y
Cancer Res; 2021 Feb; 81(4):898-909. PubMed ID: 33277368
[TBL] [Abstract][Full Text] [Related]
24. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
[TBL] [Abstract][Full Text] [Related]
25. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
26. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization.
Graves B; Thompson T; Xia M; Janson C; Lukacs C; Deo D; Di Lello P; Fry D; Garvie C; Huang KS; Gao L; Tovar C; Lovey A; Wanner J; Vassilev LT
Proc Natl Acad Sci U S A; 2012 Jul; 109(29):11788-93. PubMed ID: 22745160
[TBL] [Abstract][Full Text] [Related]
27. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
28. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
[TBL] [Abstract][Full Text] [Related]
29. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
30. Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy.
Niu F; Yan J; Ma B; Li S; Shao Y; He P; Zhang W; He W; Ma PX; Lu W
Biomaterials; 2018 Jun; 167():132-142. PubMed ID: 29571049
[TBL] [Abstract][Full Text] [Related]
31. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.
Kojima K; Konopleva M; Samudio IJ; Shikami M; Cabreira-Hansen M; McQueen T; Ruvolo V; Tsao T; Zeng Z; Vassilev LT; Andreeff M
Blood; 2005 Nov; 106(9):3150-9. PubMed ID: 16014563
[TBL] [Abstract][Full Text] [Related]
32. Monitoring p53 by MDM2 and MDMX is required for endocrine pancreas development and function in a spatio-temporal manner.
Zhang Y; Zeng SX; Hao Q; Lu H
Dev Biol; 2017 Mar; 423(1):34-45. PubMed ID: 28118981
[TBL] [Abstract][Full Text] [Related]
33. Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach.
Li K; Hu W; Wang Y; Chen W; Wen H; Liu J; Li W; Wang B
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2288810. PubMed ID: 38059334
[TBL] [Abstract][Full Text] [Related]
34. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
Barakat K; Mane J; Friesen D; Tuszynski J
J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
[TBL] [Abstract][Full Text] [Related]
35. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological activation of wild-type p53 in the therapy of leukemia.
Kojima K; Ishizawa J; Andreeff M
Exp Hematol; 2016 Sep; 44(9):791-798. PubMed ID: 27327543
[TBL] [Abstract][Full Text] [Related]
37. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
[TBL] [Abstract][Full Text] [Related]
38. Peptide activators of the p53 tumor suppressor.
Zhan C; Lu W
Curr Pharm Des; 2011; 17(6):603-9. PubMed ID: 21391910
[TBL] [Abstract][Full Text] [Related]
39. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions.
Li C; Pazgier M; Li C; Yuan W; Liu M; Wei G; Lu WY; Lu W
J Mol Biol; 2010 Apr; 398(2):200-13. PubMed ID: 20226197
[TBL] [Abstract][Full Text] [Related]
40. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
